409 related articles for article (PubMed ID: 25792124)
21. Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial.
Bonaca MP; Scirica BM; Braunwald E; Wiviott SD; O'Donoghue ML; Murphy SA; Morrow DA
J Am Coll Cardiol; 2014 Dec; 64(22):2309-17. PubMed ID: 25465416
[TBL] [Abstract][Full Text] [Related]
22. Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword!
Bhandari B; Mehta B
Recent Adv Cardiovasc Drug Discov; 2014; 9(2):73-7. PubMed ID: 26104312
[TBL] [Abstract][Full Text] [Related]
23. Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50).
Berg DD; Bonaca MP; Braunwald E; Corbalan R; Goto S; Kiss RG; Murphy SA; Scirica BM; Spinar J; Morrow DA
Am J Cardiol; 2016 Apr; 117(7):1055-8. PubMed ID: 26876014
[TBL] [Abstract][Full Text] [Related]
24. Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER.
White HD; Huang Z; Tricoci P; Van de Werf F; Wallentin L; Lokhnygina Y; Moliterno DJ; Aylward PE; Mahaffey KW; Armstrong PW
J Am Heart Assoc; 2014 Jul; 3(4):. PubMed ID: 25012288
[TBL] [Abstract][Full Text] [Related]
25. Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2°P-TIMI 50 trial.
Patel SM; Morrow DA; Kidd SK; Goodrich EL; Scirica BM; Bonaca MP
Vasc Med; 2019 Apr; 24(2):159-161. PubMed ID: 30868939
[No Abstract] [Full Text] [Related]
26. Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial.
Kosova EC; Bonaca MP; Dellborg M; He P; Morais J; Oude Ophuis T; Scirica BM; Tendera M; Theroux P; Braunwald E; Morrow DA
Eur Heart J Acute Cardiovasc Care; 2017 Mar; 6(2):164-172. PubMed ID: 27075924
[TBL] [Abstract][Full Text] [Related]
27. State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
Du M; Chase M; Oguz M; Davies G
Curr Med Res Opin; 2017 Sep; 33(9):1535-1543. PubMed ID: 28277861
[TBL] [Abstract][Full Text] [Related]
28. A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction.
Whalen JD; Davies G; Du M; Oguz M; Bash LD; Ozer-Stillman I
Am J Cardiovasc Drugs; 2016 Aug; 16(4):285-295. PubMed ID: 27262432
[TBL] [Abstract][Full Text] [Related]
29. Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition.
Ungar L; Rodriguez F; Mahaffey KW
Coron Artery Dis; 2016 Nov; 27(7):604-15. PubMed ID: 27398626
[TBL] [Abstract][Full Text] [Related]
30. Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
Armaganijan LV; Alexander KP; Huang Z; Tricoci P; Held C; Van de Werf F; Armstrong PW; Aylward PE; White HD; Moliterno DJ; Wallentin L; Chen E; Harrington RA; Strony J; Mahaffey KW; Lopes RD
Am Heart J; 2016 Aug; 178():176-84. PubMed ID: 27502866
[TBL] [Abstract][Full Text] [Related]
31. Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial.
Harskamp RE; Clare RM; Ambrosio G; Held C; Lokhnygina Y; Moliterno DJ; White HD; Aylward PE; Armstrong PW; Mahaffey KW; Harrington RA; Van de Werf F; Wallentin L; Strony J; Tricoci P
Eur Heart J Acute Cardiovasc Care; 2017 Mar; 6(2):155-163. PubMed ID: 26895973
[TBL] [Abstract][Full Text] [Related]
32. Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial.
Held C; Tricoci P; Huang Z; Van de Werf F; White HD; Armstrong PW; Ambrosio G; Aylward PE; Moliterno DJ; Wallentin L; Chen E; Erkan A; Jiang L; Strony J; Harrington RA; Mahaffey KW
Eur Heart J Acute Cardiovasc Care; 2014 Sep; 3(3):246-56. PubMed ID: 24627331
[TBL] [Abstract][Full Text] [Related]
33. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial.
Leonardi S; Tricoci P; White HD; Armstrong PW; Huang Z; Wallentin L; Aylward PE; Moliterno DJ; Van de Werf F; Chen E; Providencia L; Nordrehaug JE; Held C; Strony J; Rorick TL; Harrington RA; Mahaffey KW
Eur Heart J; 2013 Jun; 34(23):1723-31. PubMed ID: 23530022
[TBL] [Abstract][Full Text] [Related]
34. Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.
Cheng JW
Vasc Health Risk Manag; 2016; 12():263-8. PubMed ID: 27366081
[TBL] [Abstract][Full Text] [Related]
35. Vorapaxar: first global approval.
Poole RM; Elkinson S
Drugs; 2014 Jul; 74(10):1153-63. PubMed ID: 24962425
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery.
van Diepen S; Tricoci P; Podder M; Westerhout CM; Aylward PE; Held C; Van de Werf F; Strony J; Wallentin L; Moliterno DJ; White HD; Mahaffey KW; Harrington RA; Armstrong PW
J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26672080
[TBL] [Abstract][Full Text] [Related]
37. Vorapaxar monotherapy for secondary stroke prevention: A call for randomized trial.
Serebruany VL; Kim MH; Hanley DF
Int J Stroke; 2016 Aug; 11(6):614-7. PubMed ID: 26860124
[TBL] [Abstract][Full Text] [Related]
38. Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke.
Shinohara Y; Goto S; Doi M; Jensen P
J Stroke Cerebrovasc Dis; 2012 May; 21(4):318-24. PubMed ID: 20947374
[TBL] [Abstract][Full Text] [Related]
39. Review of vorapaxar for the prevention of atherothrombotic events.
Wang A
Expert Opin Pharmacother; 2015; 16(16):2509-22. PubMed ID: 26480240
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
Patel MR; Becker RC; Wojdyla DM; Emanuelsson H; Hiatt WR; Horrow J; Husted S; Mahaffey KW; Steg PG; Storey RF; Wallentin L; James SK
Eur J Prev Cardiol; 2015 Jun; 22(6):734-42. PubMed ID: 24830710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
